Le Guennec P, Dromer C, Sixou L, Marc V, Coustals P, Fournié B
Service de Clinique de Rhumatologie, Centre Hospitalier Universitaire- Hôpital de Purpan, Toulouse.
Rev Rhum Ed Fr. 1994;61(7-8):485-90.
Thirty-six patients with giant cells arteritis were studied retrospectively. Histological examination of the temporal artery or another artery was positive in 95% of cases. Mean follow-up was five years. A synthetic antimalarial was used in every case. Two groups were differentiated. One (Group I) was composed of 21 patients who were given the antimalarial drug as part of the first-line therapy, either with a corticosteroid in a mean dose of 36 mg/d (18 patients) or with a nonsteroidal antiinflammatory agent. The other group (Group II) included 15 patients in whom the antimalarial was used after a period of corticosteroid therapy, because of steroid-dependency (n = 5) or adverse effects (n = 9), or as part of a routinely used protocol (n = 1). Withdrawal of the corticosteroid was achieved in 81% of cases, after a mean interval of 15 months. Many patients discontinued the corticosteroid after less than one year. The 18 Group I patients who were given a corticosteroid were all able to discontinue this drug. The overall recovery rate was 58%; mean time to recovery was 33 months with a mean follow-up of 52 months. There were no recurrences at discontinuation of the treatment. Adverse effects of antimalarial therapy were recorded in 30.5% of patients and required discontinuation of the drug in 19%. The most often used regimen was hydroxychloroquine (40 mg/d) for at least two years and prednisone 20 to 30 mg/d for two months, in the absence of vascular complications.(ABSTRACT TRUNCATED AT 250 WORDS)
对36例巨细胞动脉炎患者进行了回顾性研究。颞动脉或其他动脉的组织学检查在95%的病例中呈阳性。平均随访时间为5年。所有病例均使用了一种合成抗疟药。分为两组。一组(第一组)由21例患者组成,他们将抗疟药作为一线治疗的一部分,其中18例患者联合平均剂量为36mg/d的皮质类固醇使用,另外3例联合非甾体抗炎药使用。另一组(第二组)包括15例患者,他们因依赖类固醇(5例)或出现不良反应(9例),或作为常规治疗方案的一部分(1例),在接受一段时间的皮质类固醇治疗后使用抗疟药。81%的病例在平均15个月的间隔后成功停用了皮质类固醇。许多患者在不到一年的时间内就停用了皮质类固醇。接受皮质类固醇治疗的18例第一组患者均能够停用该药物。总体恢复率为58%;平均恢复时间为33个月,平均随访时间为52个月。治疗停药后无复发。30.5%的患者记录了抗疟治疗的不良反应,19%的患者需要停药。最常用的方案是羟氯喹(40mg/d)至少使用两年,泼尼松20至30mg/d使用两个月,前提是没有血管并发症。(摘要截断于250字)